HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors

International Journal of Cancer

Volumn 108, Issue 4, 2004, Pages 540-548

  Half, Elizabeth ^a   Broaddus, Russell ^a   Danenberg, Kathleen D ^b   Danenberg, Peter V ^c   Ayers, Gregory D ^a   Sinicrope, Frank A ^a,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Response Genetics Inc   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Colorectal cancer; HER2 neu (c erbB 2); Phosphorylation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA;

ARTICLE; BREAST CARCINOMA; CELL FRACTIONATION; CELL LINE; CELL MEMBRANE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE FREQUENCY; GENE LOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE NEU; PATHOLOGY; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLONIC NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0347417902     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11599     Document Type: Article

References (67)

1. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996;15:2452-67.
2. Venkateswarlu S, Dawson DM, St. Clair P, Gupta A, Willson JK, Brattain MG. Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. Oncogene 2002;21:78-86.
3. Pinkas-Kramarski R, Shelly M, Guarino BC, Wang LM, Lyass L, Alroy I, Alimandi M, Kuo A, Moyer JD, Lavi S, Eisenstein M, Ratzkin BJ, et al. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol 1998;18:6090-101.
4. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67.
5. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-25.
6. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2. the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55.
7. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y. A hierarchical network of interoceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276-87.
8. Akiyama T, Matsuda S, Namba Y, Saito T, Toyoshima K, Yamamoto T. The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain. Mol Cell Biol 1991;11:833-42.
9. DiGiovanna MP, Lerman MA, Coffey RJ, Muller WJ, Cardiff RD, Stern DF. Active signaling by Neu in transgenic mice. Oncogene 1998;17:1877-84.
10. Segatto O, Lonardo F, Helin K, Wexler D, Fazioli F, Rhee SG, Di Fiore PP. erbB-2 autophosphorylation is required for mitogenic action and high-affinity substrate coupling. Oncogene 1992;7:1339-46.
11. Ben-Levy R, Paterson HF, Marshall CJ, Yarden Y. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J 1994;13:3302-11.
12. Kapitanovic S, Radosevic S, Kapitanovic M, Andelinovic S, Ferencic Z, Tavassoli M, Primorac D, Sonicki Z, Spaventi S, Pavelic K, Spaventi R. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997;112:1103-13.
13. Osako T, Miyahara M, Uchino S, Inomata M, Kitano S. Kobayashi M. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 1998;55:548-55.
14. McKay JA, Loane JF, Ross VG, Ameyaw M-M, Murray GI, Cassidy J, McLeod HL. c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer 2002;86:568-73.
15. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
16. Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998;52:65-77.
17. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
18. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Salamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2000;20:719-26.
19. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-68.
20. Sasano H, Date F, Imatani A, Asaki S, Nagura H. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 1993;24:584-9.
21. Micke P, Hengstler JG, Ros R, Bittinger F, Metz T, Gebhard S, Beeh KM, Oesch F, Buhl R. c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis. Int J Cancer 2001;92:474-9.
22. Zinner RG, Kim J, Herbst RS. Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer 2002;37:17-27.
23. Gu K, Mes-Masson AM, Gauthier J, Saad F. Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. Cancer Lett 1996;99:185-9.
24. Morote J, de Torres I, Caceres C, Vallejo C, Schwartz S, Jr., Reventos J. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. Int J Cancer 1999;84:421-5.
25. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
26. Yazici H, Dolapcioglu K, Buyru F, Dalay N. Utility of c-erbB-2 expression in tissue and sera of ovarian cancer patients. Cancer Invest 2000;18:110-4.
27. Keshgegian AA, Cnaan A. erbB-2 oncoprotein expression in breast carcinoma. Poor prognosis associated with high degree of cytoplasmic positivity using CB-11 antibody. Am J Clin Pathol 1997;108:456-63.
28. Taylor SL, Platt-Higgins A, Rudland PS, Winstanley JH, Barraclough R. Cytoplasmic staining of c-erbB-2 is not associated with the presence of detectable c-erbB-2 mRNA in breast cancer specimens. Int J Cancer 1998;76:459-63.
29. Zschiesche W, Schonborn I, Minguillon C, Spitzer E. Significance of immunohistochemical c-erbB-2 product localization pattern for prognosis of primary human breast cancer. Cancer Lett 1994;81:89-94.
30. Harpole DH Jr, Marks JR, Richards WG, Herndon JE 2nd, Sugarbaker DJ. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. Clin Cancer Res 1995;1:659-64.
31. Piyathilake CJ, Frost AR, Manne U, Weiss H, Bell WC, Heimburger DC, Grizzle WE. Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clin Cancer Res 2002;8:734-44.
32. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI. Sliwkowski MX, DuBois RN. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001;120:1713-9.
33. Half EE, Tang X, Spivak-Kroizman T, Broaddus R, Ayers GD, Sinicrope FA. HER-2/neu expression and activation in human colorectal cancers. Proc Am Assoc Cancer Res 2002;43:603.
34. Kirkland SC. Dome formation by a human colonic adenocarcinoma cell line (HCA-7). Cancer Res 1985;45:3790-5.
35. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99:2254-9.
36. Morgan JM. A protocol for preparing cell suspensions with formalin fixation and paraffin embedding which minimizes the formation of cell aggregates. J Cell Pathol 2001;5:171-80.
37. Beahrs OH. Staging of cancer of the colon and rectum. Cancer 1992;70:1393-6.
38. Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P, DeMeester SR, Bremner CG, Tsai PI, et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000;4:135-42.
39. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996;6:995-1001.
40. Hopman AH, Ramaekers FC, Raap AK, Beck JL, Devilee P, van der Ploeg M, Vooijs GP. In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochemistry 1988;89:307-16.
41. Chavany C, Mimnaugh E, Miller P, Bitton R, Nguyen P, Trepel J, Whitesell L, Schnur R, Moyer J, Neckers L. p185erbB2 binds to GRP94 in vivo. Dissociation of the p 185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J Biol Chem 1996;271:4974-7.
42. Nathanson DR, Culliford AT IV, Shia J, Chen B, D'Alessio M, Zeng Z-S, Nash GM, Gerald W, Barany F, Paty PB. HER 2/neu expression and gene amplification in colon cancer. Int J Cancer Res 2003;105:796-802.
43. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
44. Joh J-W, Noh D-Y, Bae CD, Choi K-J, Park J-B. Amplification and over-expression of erbB-2 oncogene in primary human breast tumors. Exp Mol Med 1996;28:47-53.
45. Kraus MH, Popescu NC, Amsbaugh SC, King CR. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 1987;6:605-10.
46. Quatacker J, De Potter C, Van Daele S, Roels H. The selective counterstaining of the plasma membrane improves the immunoelectron microscopic detection of neu protein at the cell border. Acta Histochem Suppl 1990;40:105-7.
47. De Potter CR, Quatacker J, Maertens G, Van Daele S, Pauwels C, Verhofstede C, Eechaute W, Roels H. The subcellular localization of the neu protein in human normal and neoplastic cells. Int J Cancer 1989;44:969-74.
48. Grzanka A, Skok Z, Janiak A, Grzanka D. Immunoelectron microscopical identification of the c-erbB-2 oncoprotein in patients with laryngeal squamous cell carcinoma. Acta Histochem 2000;102:403-11.
49. Wong RF, Kuang J, Xiufen L, Kuwada S. Modulation of growth factor receptor expression and function by integrins in colon cancer cells. Am Gastroenterol Assn 2003;124(Suppl. 1):A57.
50. Half E, Sun Y, Sinicrope FA. Anti-HER-2 antibody inhibits COX-2 expression and reduces survival of human colon cancer cells. AACR Frontiers Cancer Prevent Conf 2002;145.
51. Worthylake R, Opresko LK, Wiley HS. ErbB-2 amplification inhibits downregulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 1999;274:8865-74.
52. Wiley HS. Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res 2003;284:78-88.
53. McKay JA, Murray LJ, Curran S, Ross VG, Clark C, Murray GI, Cassidy J, McLeod HL. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 2002;38:2258-64.
54. Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang S-Y, Pusztai L, Buzdar A, Bacus SS. Expression of cerbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res 2001;7:171-7.
55. DiGiovanna MP, Carter D, Flynn SD, Stern DF. Functional assay for HER-2/neu demonstrates active signaling in a minority of HER-2/neu-overexpressing invasive human breast tumours. Br J Cancer 1996;74:802-6.
56. Thor AD, Liu S, Edgerton S, Moore D 2nd, Kasowitz KM, Benz CC, Stern DF, DiGiovanna MP. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol 2000;18:3230-9.
57. Oshima CT, Lanzoni VP, Iriya K, Forones NM. C-erbB2 oncoprotein expression in gastric carcinoma: correlation with clinical stage and prognosis. Int J Biol Markers 2001;16:250-4.
58. Rotter M, Block T, Busch R, Thanner S, Hofler H. Expression of HER-2/neu in renal-cell carcinoma. Correlation with histologic subtypes and differentiation. Int J Cancer 1992;52:213-7.
59. Moriki T, Takahashi T, Hiroi M, Yamane T, Hara H. Histological grade in invasive ductal carcinoma of breast correlates with the proliferative activity evaluated by BrdU: an immunohistochemical study including correlations with p53, c-erbB2, and estrogen receptor status. Pathol Int 1996;40:417-25.
60. Zhang K, Salto-Tellez M, Do E, Putti TC, Koay ESC. Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol 2003;34:362-8.
61. Warnberg F, Nordgren H, Bergkvist L, Holmberg L. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer 2001;85:869-74.
62. Sinicrope FA, Roddey G, Lemoine M, Ruan S, Stephens LC, Frazier ML, Shen Y, Zhang W. Loss of p21WAF1/Cip1 protein expression accompanies progression of sporadic colorectal neoplasms but not hereditary nonpolyposis colorectal cancers. Clin Cancer Res 1998;4:1251-61.
63. el-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, Hill DE, Healy E, Rees JL, Hamilton SR, et al. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995;55:2910-9.
64. Giani C, Casalini P, Pupa SM, De Vecchi R, Ardini E, Colnaghi MI, Giordano A, Menard S. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation. Oncogene 1998;17:425-32.
65. Bacus SS, Huberman E, Chin DM, Kiguchi K, Simpson S, Lippman M, Lupu R. A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells. Cell Growth Differ 1992;3:401-11.
66. Chamberlain NL, Ward RL, Hawkins NJ. Clinicopathological significance of erbB-2 expression in colorectal carcinoma. Oncol Rep 1999;6:527-31.
67. Berney C, Fisher RJ, Yang JL, Russell PJ, Crowe PJ. Protein markers in colorectal cancer. Ann Surg 1999;230:179-84.